The Clinitech Laboratory IPO Subscription Status started on July 25, 2024, and it is also being subscribed to by QIB, NII, and RII. The Clinitech Laboratory IPO opened on July 25, 2024, and closes on July 29, 2024. Clinitech Laboratory IPO is to raise ₹5.78 crores through its fresh Issue and the Clinitech Laboratory IPO price band is fixed at ₹59 per share. You can check Clinitech Laboratory IPO GMP here.
Clinitech Laboratory Limited operates 8 diagnostic centers in and around Thane and Navi Mumbai, offering diagnostic and healthcare tests and services. The company performs over 300,000 tests annually in its NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited labs, which are equipped with modern technology and high-end equipment. The company in Airoli, Navi Mumbai has been awarded a Certificate of Accreditation by NABL (National Accreditation Board for Testing and Calibration Laboratories) in line with ISO 15189:2012.
Clinitech Laboratory IPO reserved shares in this IPO, 50% for NII, and 50% for the retail category have been reserved. To know the Clinitech Laboratory IPO Subscription Status, you can see the below-day Subscription.
Clinitech Laboratory IPO Review :
👉 Clinitech Laboratory IPO Show Review ….👈
- ■ The company is engaged in providing diagnostic and healthcare tests related services.
- ■ The company top line & bottom line stable growth.
- ■ The PE ratio of the company is slightly aggressive.
- ■ Based on FY24 earnings, the issue is exorbitantly priced.
- ■ The company Issue price is slightly aggressive based on the PE Ratio.
- ■ Based on FY24 the issue appears aggressive, Investors can avoid the issue.
Clinitech Laboratory IPO Subscription Status {Live Update} :
The total Clinitech Laboratory IPO Subscription Status subscribed 38.96x times so far, with NII subscribed 23.28x times & RII 49.61x times on Day 3. (Closed)
| Category | Day 1 | Day 2 | Day 3 |
| NII : | 0.62x | 1.33x | 23.28x |
| RII : | 4.33x | 10.10x | 49.61x |
| Total : | 2.61x | 6.03x | 38.96x |
Clinitech Laboratory IPO Shares Offer :
| Category | Reservation | Shares | Amount (₹ Cr) |
| NII : | 50.00% | 301,200 | 2.89 |
| RII : | 50.00% | 301,200 | 2.89 |
| MMRP : | 5.18% | 31200 | 0.30 |
| Total : | 100% | 602,400 | 5.78 |
Investor Categories Define :
■ Qualified Institutional Buyers (QIB): Financial Institutions, Banks, FIIs, Mutual Funds, insurance companies, and pension schemes.
■ Non-Institutional Investors(NII): Retail Individual Investors, NRIs, Companies, Trusts, etc
● sNII (bids below Rs 10L): The Small NII category is for NII investors who bid for shares between Rs 2 lakhs to Rs 10 lakhs. The 1/3 of NII category shares are reserved for the Small NII sub-category.
● bNII (bids above Rs 10L): The Big NII category is for NII investors who bid for shares worth more than Rs 10 Lakhs. The 2/3 of NII category shares are reserved for the Big NII subcategory.
■ Retail Individual Investors (RII): Retail Individual Investors or NRIs
■ Employee (EMP): Eligible Employees
■ Others: Eligible Shareholders
Clinitech Laboratory IPO Subscription Status FAQs :
How much was the total Clinitech Laboratory IPO Subscription Status?
The total Clinitech Laboratory IPO Subscription Status is 38.96x times Day 3.
How much is the Clinitech Laboratory IPO retail subscription Status?
Clinitech Laboratory IPO Retail Subscription 49.61x times Day 3.
How much did Clinitech Laboratory IPO NII subscribe?
Clinitech Laboratory IPO NII Subscription 23.61x times Day 3.
When is the Clinitech Laboratory IPO Allotment Date?
Clinitech Laboratory’s IPO allotment date is July 30, 2024.
When is Clinitech Laboratory’s IPO Listing Date?
Clinitech Laboratory’s IPO listing date is August 01, 2024. The IPO is to be listed on BSE, SME.
| Clinitech Laboratory IPO GMP: Click Here Clinitech Laboratory IPO Details: Click Here Clinitech Laboratory IPO Allotment: Click Here Clinitech Laboratory IPO Listing: Click Here |
All Clinitech Laboratory IPO-related links are available here. If you want to know the details click here.
Disclaimer: STOCK MARKET INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME-RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.